Don W. Cleveland is an American cancer biologist and neurobiologist. Cleveland is currently the Department Chair of Cellular and Molecular Medicine and Distinguished Professor of Medicine, Cellular and Molecular Medicine and Neurosciences at the University of California at San Diego, and Head, Laboratory for Cell Biology at the San Diego branch of Ludwig Cancer Research.
Biography
Cleveland grew up in Las Cruces, New Mexico. He earned a B.S. in physics in 1972 from New Mexico State University, and graduated as the valedictorian for the College of Arts and Sciences. Cleveland started graduate school at Princeton University in 1972, switching mid-year into biochemistry. He worked with Marc Kirschner and graduated with a Ph.D. in 1977. Cleveland's doctoral dissertation was titled "Purification and properties of tau, a microtubule associated protein which induces assembly of microtubules from purified tubulin". As a graduate student, Cleveland provided the initial identification and characterization of tau, showing it to have characteristics of a natively unfolded protein. Tau is now recognized to accumulate in Alzheimer's disease and to be the basis for chronic brain injury. He also developed and published a peptide fingerprinting technique that was so popular that it became a citation classic Cleveland did postdoctoral work with William J. Rutter at the University of California at San Francisco from 1978 to 1981. Cleveland was the first to clone tubulinactin and keratin From 1981 through 1995, Cleveland was on the faculty of the Department of Biological Chemistry at the Johns Hopkins University School of Medicine. In 1995, he accepted a position at the San Diego Branch of Ludwig Cancer Research at the University of California at San Diego. Since 2008, he has been Chair of the Department of Cellular and Molecular Medicine.
Contributions to Science
Cleveland has made pioneering discoveries of the mechanisms of chromosome movement and cell-cycle control during normal cellular division, as well as of the principles of neuronal cell development and their relationship to the defects that contribute to inherited neurodegenerative disease. Cleveland's research looks at the molecular genetics of axonal growth and motor neuron disease and the cell biology of mammalian chromosome movement. Most recently, his research has achieved a significant breakthrough in treating Huntington's disease, an inherited and degenerative brain disorder for which there is no cure. A one-time injection of a new DNA-based drug treatment - known as ASO - blocked the activity of the gene whose mutation causes the disease. A single treatment silenced the mutated gene responsible for the disease, slowing and partially reversing progression of the fatal neurodegenerative disorder in animal models. This drug, called IONIS-HTTRx, was developed by scientists at Ionis Pharmaceuticals in collaboration with partners CHDI Foundation, Roche Pharmaceuticals and academic collaborators at University of California, San Diego and is now in a Phase 1/2a clinical study.
Books
Cell and Molecular Biology of the Cytoskeleton: Molecular Mechanisms Controlling Tubulin Synthesis Edited by Jerry W. Shay , With Toni L. Williamson, Mouse Models in the Study of Genetic Neurological Disorders: Mouse Models of Amyotrophic Lateral Sclerosis Edited by Brian Popko , With Nicholas G. Theodorakis, Control of Messenger RNA Stability: Translationally Coupled Degradation of Tubulin mRNA Edited By Joel Belasco and George Brawerman
